Plaque Psoriasis 
The MD Magazine Plaque Psoriasis condition center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

Latest Headlines

With Age Comes Reduced Treatment Access for Psoriasis Patients
Age matters when it comes to patients’ access to psoriasis treatment.
Biologic drug secukinumab (Cosentyx/Novartis), already FDA approved in January 2015 to treat chronic plaque psoriasis, has now been approved for two new indications: the treatment of active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA).
Graded drug challenges are considered the gold standard for evaluating patients with a low-risk history of a prior adverse drug reactions – like a mild rash or unknown reaction to penicillin as a child.
Seniors who developed the painful rash commonly known as shingles may also be at higher risk of suffering a stroke or heart attack.
Study results suggest that a treatment for psoriasis and multiple sclerosis may induce a dangerous adverse effect, particularly in women. The finding is potentially important, because while treatment with fumaric acid esters has been around for more than 40 years, it is now being used more widely in the United States, Germany, and other areas.
College kids who break out or get hives can, in fact, blame some of their skin problems on heightened levels of psychological stress.
Recent research has discovered evidence potentially supporting a parent-of-origin effect in psoriatic disease.
It is generally well-understood that smoking cigarettes exacerbates symptoms of psoriasis. But recent study results clarify and strengthen the link between smoking and the development of psoriatic lesions.
When I first started seeing patients on my own, I would get annoyed when patients came in with printouts from WebMD, Health.com, or the dreaded Wikipedia.

Most Popular


$vacMongoViewPlus$ $vAR$